Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Preventing the build up of dangerous biofilms, ESCMID publishes guidelines

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organization that explores the risks and best practices in infectious disease – advocates the need for greater education, guidance and research on the build-up, treatment and prevention of biofilms, which contribute to antimicrobial resistance.

2 Sep 2015

Familial hypercholesterolemia patients can benefit from alirocumab drug

Alirocumab lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials presented at ESC Congress today.

2 Sep 2015

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

27 Aug 2015

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended June 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

27 Aug 2015

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

26 Aug 2015

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Individuals who received the flu vaccine were protected for up to 6 months post-vaccination, the duration of most flu seasons, according to a study presented at the 2015 International Conference on Emerging Infectious Diseases.

25 Aug 2015

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

24 Aug 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

Three projects that focus on improving global health win DEBUT Challenge

Three unique projects focused on improving global health won the National Institutes of Health's Design by Biomedical Undergraduate Teams (DEBUT) Challenge. The winners showed exemplary initiative in designing tools for a less expensive, portable device to monitor HIV treatment, a new surgical clamp to treat drooping eyelids, and a low-cost patient monitor.

24 Aug 2015

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge."

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

Experimental MERS-CoV vaccine shows promise in monkeys and camels

National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels.

20 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

Antibody News and Research

Further Reading

Preventing the build up of dangerous biofilms, ESCMID publishes guidelines

Familial hypercholesterolemia patients can benefit from alirocumab drug

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

TSRI, Janssen collaborate to find universal flu vaccine

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Three projects that focus on improving global health win DEBUT Challenge

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Experimental MERS-CoV vaccine shows promise in monkeys and camels

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News